The road map to oral bioavailability: An industrial perspective

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 4, 2006, Pages 591-608

  Thomas, V Hayden ^a   Bhattachar, Shobha ^a   Hitchingham, Linda ^a   Zocharski, Philip ^a   Naath, Maryanne ^a   Surendran, Narayanan ^a   Stoner, Chad L ^a   El Kattan, Ayman ^a  

^a PFIZER INC   (United States)

Author keywords

Absorption; ADME optimisation; Bioavailability; Distribution; Drug discovery; Elimination; Metabolism; Pharmacokinetics; Solubility

Indexed keywords

COMBINATORIAL CHEMISTRY; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG RESEARCH; IN VIVO STUDY; LIPOPHILICITY; REVIEW; BIOAVAILABILITY; CHEMISTRY; DRUG INDUSTRY; HUMAN; INTESTINE ABSORPTION; LIVER CELL; METABOLISM; PERMEABILITY; SOLUBILITY;

DRUG;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG INDUSTRY; HEPATOCYTES; HUMANS; INTESTINAL ABSORPTION; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 33747862996     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.4.591     Document Type: Review

References (120)

1. DIMASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation: new estimates of drug development costs. J. Health Econ. (2003) 22(2):151-185. A good overview for the financial impact of poor decision making.
2. GRIBBON P, SEWING A: High-throughput drug discovery: what can we expect from HTS? Drug Discov. Today (2005) 10(1):17-22.
3. LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (2001) 46(1-3):3-26. Thorough overview describing several discovery approaches for assessing solubility and permeability.
4. VAN DE WATERBEEMD H, SMITH DA, BEAUMONT K, WALKER DK: Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. (2001) 44(9):1313-1333.
5. DI L, KERNS EH: Profiling drug-like properties in discovery research. Curr. Opin. Chem. Biol. (2003) 7(3):402-408.
6. BALANI SK, MIWA GT, GAN L-S, WU J-T, LEE FW: Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr. Top. Med. Chem. (2005) 5:1033-1038.
7. KERNS EH: High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. (2001) 90(11):1838-1858.
8. AVDEEF A, TESTA B: Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell. Mol. life Sci. (2002) 59(10):1681-1689.
9. STONER CL, CLETON A, JOHNSON K et al.: Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. Int. J. Pharm. (2004) 269(1):241-249.
10. CALDWELL GW, RITCHIE DM, MASUCCI JA, HAGEMAN W, YAN Z: The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr. Top. Med. Chem. (2001) 1(5):353-366.
11. PARROTT N, PAQUEREAU N, COASSOLO P, LAVE T: An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci. (2005) 94(10):2327-2343.
12. HELLRIEGEL ET, BJORNSSON TD, HAUCK WW: Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. (1996) 60(6):601-607.
13. LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods (2000) 44(1):235-249. Provides a prospective to chemical matter output obtained from both HTS and rational drug design approaches.
14. VEBER DF, JOHNSON SR, CHENG HY et al.: Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. (2002) 45(12):2615-2623.
15. PALM K, STENBERG P, LUTHMAN K, ARTURSSON P: Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. (1997) 14(5):568-571.
16. FLYNN GL, YALKOWSKY SH, ROSEMAN TJ: Mass transport phenomena and models: theoretical concepts. J. Pharm. Sci. (1974) 63(4):479-510.
17. AMIDON GL, LENNERNAS H, SHAH VP, CRISON JR: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. (1995) 12(3):413-420.
18. GRANT DJW, HIGUCHI T: Solubility behavior of organic compounds. WH Saunders Jr (Ed.), John Wiley and Sons, New York, USA (1990):12-88.
19. DEHRING KA, WORKMAN HL, MILLER KD, MANDAGERE A, POOLE SK: Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility. J. Pharm. Biomed. Anal. (2004) 36(3):447-456.
20. LIPINSKI CA: Solubility in water and DMSO: Issues and potential solutions. In: Pharmaceutical Profiling in Drug Discovery for Lead Selection. RT Borchardt, EH Kerns, CA Lipinski et al. (Eds), AAPS Press, Arlington, VA, USA (2004):93-126.
21. JAIN N, YALKOWSKY SH: Estimation of the aqueous solubility I: application to organic nonelectrolytes. J. Pharm. Sci. (2001) 90(2):234-252.
22. YALKOWSKY SH: Solubility and miscibility. In: Solubility and solubilization in aqueous media. Oxford University Press, New York, USA (1999):49-80.
23. ANDO HY, RADEBAUGH GW: Property-based drug design and preformulation. In: Remington: The Science and Practice of Pharmacy. Philadelphia UotSi (Ed.) Lippincott, Williams and Wilkins, Philidelphia, PA, USA (2005):720-744.
24. GOOSEN C, LAING TJ, DU PJ, GOOSEN TC, FLYNN GL: Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs. Pharm. Res. (2002) 19(1):13-19.
25. NIKAM SS, CORDON JJ, ORTWINE DF et al.: Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivatives. J. Med. Chem. (1999) 42(12):2266-2271.
26. VACCA JP, DORSEY BD, SCHLEIF WA et al.: L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA (1994) 91(9):4096-4100.
27. MILBANK JB, TERCEL M, ATWELL GJ et al.: Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. J. Med. Chem. (1999) 42(4):649-658.
28. CHOWHAN ZT: pH-solubility profiles or organic carboxylic acids and their salts. J. Pharm. Sci. (1978) 67(9):1257-1260.
29. KRAMER SF, FLYNN GL: Solubility of organic hydrochlorides. J. Pharm. Sci. (1972) 61(12):1896-1904.
30. LI S, HE H, PARTHIBAN LJ, YIN H, SERAJUDDIN AT: IV-IVC considerations in the development of immediate-release oral dosage form. J. Pharm. Sci. (2005) 94(7):1396-1417.
31. RINAKI E, DOKOUMETZIDIS A, MACHERAS P: The mean dissolution time depends on the dose/solubility ratio. Pharm. Res. (2003) 20(3):406-408.
32. JIANG W, GUAN J, MACIELAG MJ et al.: Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction. J. Med. Chem. (2005) 48(6):2126-2133.
33. JOHNSON KC, SWINDELL AC: Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. (1996) 13:1795-1798.
34. OH DM, CURL RL, AMIDON GL: Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res. (1993) 10(2):264-270.
35. YAKOU S, YAMAZAKI S, SONOBE T et al.: Particle size distribution affects the human bioavailability of phenytoin. Chem. Pharm. Bull. (1986) 34(10):4400-4402.
36. LIVERSIDGE GG, CUNDY KC: Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. (1995) 125(1):91-97.
37. NELLANS HN: Intestinal calcium absorption. Interplay of paracellular and cellular pathways. Miner. Electrolyte Metab. (1990) 16(2-3):101-108.
38. KARLSSON J, UNGELL A, GRASJO J, ARTURSSON P: Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur. J. Pharm. Sci. (1999) 9(1):47-56.
39. UNGELL A-L, NYLANDER S, BERGSTRAND S, SJOBERG A, LENNERNAS H: Membrane transport of drugs in different regions of the intestinal tract of the rate. J. Pharm. Sci. (1998) 87:360-366.
40. LENNERNAS H: Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm. Res. (1995) 12(11):1573-1582.
41. PIYAPOLRUNGROJ N, ZHOU YS, LI C et al.: Cimetidine absorption and elimination in rat small intestine. Drug Metab. Dispos. (2000) 28(1):65-72.
42. FRIEND DR: Drug delivery to the small intestine. Curr. Gastroenterol. Rep. (2004) 6(5):371-376.
43. KATSURA T, INUI K: Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab. Pharmacokinet. (2003) 18(1):1-15. Good overview of intestinal transporters.
44. OH DM, HAN HK, WILLIAMSON RM et al.: Improved intestinal transport of PD-158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. J. Pharm. Sci. (2002) 91(12):2579-2587.
45. DOHERTY MM, CHARMAN WN: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. (2002) 41(4):235-253.
46. GOTOH Y, SUZUKI H, KINOSHITA S et al.: Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J. Pharmacol. Exp. Ther. (2000) 292(1):433-439.
47. ABEL S, BEAUMONT KC, CRESPI CL et al.: Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica (2001) 31(8-9):665-676.
48. EL ELA AA, HARTTER S, SCHMITT U et al.: Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds- implications for pharmacokinetics of selected substrates. J. Pharm. Pharmacol. (2004) 56(8):967-975.
49. SALPHATI L, BENET LZ: Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology (1998) 56(6):308-313.
50. BATRAKOVA EV, LI S, ALAKHOV VY, MILLER DW, KABANOV AV: Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. (2003) 304(2):845-854.
51. DIDZIAPETRIS R, JAPERTAS P, AVDEEF A, PETRAUSKAS A: Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. (2003) 11(7):391-406. Detailed analysis into P-gp substrate recognition.
52. GOMBAR VK, POLLI JW, HUMPHREYS JE, WRING SA, SERABJIT-SINGH CS: Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J. Pharm. Sci. (2004) 93(4):957-968.
53. SEELIG A, LANDWOJTOWICZ E: Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. (2000) 12(1):31-40.
54. TEODORI E, DEI S, SCAPECCHI S, GUALTIERI F: The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco (2002) 57(5):385-415.
55. LIN J, SAHAKIAN DC, DE MORAIS SM et al.: The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem. (2003) 3(10):1125-1154.
56. LI Y, SHIN YG, YU C et al.: Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-massspectrometry: application to resveratrol absorption and metabolism. Comb. Chem. High Throughput Screen. (2003) 6(8):757-767.
57. LENNERNAS H: Human intestinal permeability. J. Pharm. Sci. (1998) 87(4):403-410.
58. POLLI JE, GINSKI MJ: Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. Pharm. Res. (1998) 15(1):47-52.
59. USANSKY HH, SINKO PJ: Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a). J. Pharmacol. Exp. Ther. (2005) 314(0:391-399.
60. YEE S: In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. (1997) 14(6):763-766.
61. VAN BREEMEN RB, LI Y: Caco-2 cell permeability assays to measure drug absorption. Expert Opin. Drug Metab. Toxicol. (2005) 2005(1):175-185.
62. FISHER JM, WRIGHTON SA. WATKINS PB et al.: First-pass midazolam metabolism catalyzed by 1α,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. (1999) 289(2):1134-1142.
63. ARTURSSON P, UNGELL AL, LOFROTH JE: Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res. (1993) 10(8):1123-1129.
64. LIN LS, LANZA TJ, JR., CASTONGUAY LA et al.: Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4. Bioorg. Med. Chem. Lett. (2004) 14(9):2331-2334.
65. WALKER DK, DACK KN, DICKINSON RP et al.: Absorption, distribution, metabolism, and excretion considerations in selection of orally active indole-containing endothelin antagonist. Drug Metab. Dispos. (2001) 29(10:1424-1431.
66. RUELL JA, TSINMAN O, AVDEEF A: Acid-base cosolvent method for determining aqueous permeability of amiodarone, itraconazole, tamoxifen, terfenadine and other very insoluble molecules. Chem. Pharm. Bull. (2004) 52(5):561-565.
67. MARSILJE TH, ROSES JB, CALDERWOOD EF et al.: Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R). Bioorg. Med. Chem. Lett. (2004) 14(14):3721-3725.
68. ZHANG Z, BENET LZ: Characterization of P-glycoprotein mediated transport of KO2, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 monolayers. Pharm. Res. (1998) 15(10):1520-1524.
69. MIZUNO N, NIWA T, YOTSUMOTO Y, SUGIYAMA Y: Impact of drug transporter studies on drug discovery and development. Pbarmacol Rev. (2003) 55(3):425-461.
70. WALKER DK, ABEL S, COMBY P et al.: Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. (2005) 33(4):587-595. A very well-designed study to determine the impact of species difference.
71. CAVET ME, WEST M, SIMMIONS NL: Transport and epithelial secreation of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. (1996) 118:1389-1396.
72. 14C] erythromycin breath and urine test. Am. J. Physiol. Gastrointest. Liver Physiol. (2003) 285(3):G470-G482.
73. WU X, WHITFIELD LR, STEWART BH: Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm. Res. (2000) 17(2):209-215.
74. BOYD RA, STERN RH, STEWART BH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol. (2000) 40(1):91-98.
75. STEWART BH, KUGLER AR, THOMPSON PR, BOCKBRADER HN: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. (1993) 10(2):276-281.
76. JOHNSON BM, CHARMAN WN, PORTER CJH: An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmaSci (2002) 4(4):1-13.
77. EKINS S, KIM RB, LEAKE BF et al.: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. (2002) 61(5):974-981.
78. LIN JH, LU AYH: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. (1997) 49(4):403-449. A good overview.
79. SHEWEITA SA: Drug-metabolizing enzymes: mechanisms and functions. Curr. Drug Metab. (2000) 1(2):107-132.
80. LASKER JM, WESTER MR, ARAMSOMBATDEE E, RAUCY JL: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch. Biochem. Biophys. (1998) 353(1):16-28.
81. DAYER P, LEEMANN T, STRIBERNI R: Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450 dbl activity. Clin. Pharmacol. Ther. (1989) 45(1):34-40.
82. LANG M, PELKONEN O: Metabolism of xenobiotics and chemical carcinogenesis. IARC Sci. Publ. (1999) 148:13-22.
83. PELKONEN O, RAUNIO H, RAUTIO A, LANG M: Xenobiotic-metabolizing enzymes and cancer risk: correspondence between genotype and phenotype. IARC Sci. Publ. (1999) 148:77-88.
84. LIU L, PANG KS: The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. (2005) 33(1):1-9.
85. MEIBOHM B, BEIERLE I, DERENDORF H: How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. (2002) 41(5):329-342.
86. SCHMUCKER DL: Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging (2001) 18(11):837-851.
87. VENKATAKRISHNAN K, VON MOLTKE LL, GREENBLATT DJ: Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. (2001) 41(11):1149-1179.
88. XU C, LI CY, KONG AN: Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. (2005) 28(3):249-268.
89. SHARGEL L, YU A: Applied Biopharmaceutics and Pharmacokinetics. Appleton & Lange, Stamford, CT, USA (1999):353-398.
90. SHEWEITA SA, TILMISANYAK: Cancer and phase II drug-metabolizing enzymes. Curr. Drug Metab. (2003) 4(1):45-58.
91. DAVIES B, MORRIS T: Physiological parameters in laboratory animals and humans. Pharm. Res. (1993) 10(7):1093-1095.
92. NELSON DR, KAMATAKI T, WAXMAN DJ et al.: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol (1993) 12(1):1-51.
93. BURCHELL B, EBNER T, BAIRD S et al.: Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity. Environ. Health Perspect. (1994) 102(Suppl. 9):19-23.
94. HOSOKAWA M, MAKI T, SATOH T: Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch. Biochem. Biophys. (1990) 277(2):219-227.
95. WIDMAN M, NILSSON LB, BRYSKE B, LUNDSTROM J: Disposition of remoxipride in different species. Species differences in metabolism. Arzneim. Forsch. (1993) 43(3):287-297.
96. BERGMANN JF, LANEURY JP, DUCHENE P et al.: Pharmacokinetics of reboxetine in healthy, elderly volunteers. Eur. J. Drug Metab. Pharmacokinet. (2000) 25(3-4):195-198.
97. COCCHIARA G, BATTAGLIA R, PEVARELLO P, STROLIN BENEDETTI M: Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur. J. Drug Metab. Pharmacokinet. (1991) 16(3):231-239.
98. LIN JH, CHIBA M, BALANI SK et al.: Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. (1996) 24(10):1111-1120.
99. OBACH RS: The prediction of human clearance from hepatic microsomal metabolism data. Curr. Opin. Drug Discov. Devel (2001)4(1):36-44. Provides an overview to the use of microsomes in a discovery setting.
100. OBACH RS, BAXTER JG, LISTON TE et al.: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. (1997) 283(1):46-58.
101. LEWIS DF, DICKINS M: Substrate SARs in human P450s. Drug Discov. Today (2002) 7(17):918-925.
102. MANNHOLD R: The impact of lipophilicity in drug research: a case report on β-blockers. Mini. Rev. Med. Chem. (2005) 5(2):197-205.
103. DRAGOVICH PS, PRINS TJ, ZHOU R et al.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics. Bioorg. Med. Chem. Lett. (2002) 12(5):733-738.
104. TAGAT JR, MCCOMBIE SW, NAZARENO D et al.: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl) phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. (2004) 47(10):2405-2408.
105. ZAMORA I, AFZELIUS L, CRUCIANI G: Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J. Med. Chem. (2003) 46(12):2313-2324.
106. CRUCIANI G, CAROSATI E, DE BOECK B et al.: MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. (2005) 48(22):6970-6979.
107. BERELLINI G, CRUCIANI G, MANNHOLD R: Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. J. Med. Chem. (2005) 48(13):4389-4399.
108. HALLIFAX D, RAWDEN HC, HAKOOZ N, HOUSTON JB: Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab. Dispos. (2005) 33(12):1852-1858.
109. KEMP DC, FAN PW, STEVENS JC: Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. (2002) 30(6):694-700.
110. MORELLO KC, WURZ GT, DEGREGORIO MW: Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. (2003) 42(4):361-372.
111. HIRAOKA H, YAMAMOTO K, OKANO N et al.: Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin. Pharmacol. Ther. (2004) 75(4):324-330.
112. JAILLON P, GARDIN ME, LECOCO B et al.: Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. Clin. Pharmacol. Ther. (1989) 46(2):226-233.
113. WESTERLING D, PERSSON C, HOGLUND P: Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. Ther. Drug Monit. (1995) 17(3):287-301.
114. SHARGEL L, YU A: Applied Biopharmaceutics and Pharmacokinetics. Appleton & Lange, Stamford, CT USA (1999).
115. MASIMIREMBWA CM, BREDBERG U, ANDERSSON TB: Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin. Pharmacokinet. (2003) 42(6):515-528.
116. CALABRESE EJ: Suitability of animal models for predictive toxicology: theoretical and practical considerations. Drug Metab. Rev. (1984) 15(3):505-523.
117. SCHIAVO DM: The use of laboratory animals in toxicology: an ophthalmoscopic assessment. Toxicol. Pathol. (1990) 18(1 Pt 2):222-223.
118. WU CY, BENET LZ: Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. (2005) 22(1):11-23.
119. http://www.rxlist.com/02top.htm The top 200 prescriptions for 2002 by number of US prescriptions dispensed (2002).
120. http://www.fda.gov/cder/OPS/BCS_ guidance.htm The Biopharmaceutics Classification System (BCS) guidance (2001).